Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome

Joanna Sobiak1, Matylda Resztak1, Jacek Zachwieja2

  • 1Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Poznan, Poland.

Insights

This study investigated mycophenolic acid (MPA) pharmacodynamics in children with nephrotic syndrome (NS). IMPDH activity was measured, revealing variability and potential underexposure in younger children, impacting treatment efficacy.

Area of Science:

  • Pharmacology
  • Pediatric Nephrology
  • Immunosuppression Therapy

Background:

  • Mycophenolic acid (MPA) is an immunosuppressant used in nephrotic syndrome (NS).
  • Previous studies suggest higher MPA exposure is needed in pediatric NS compared to post-transplant patients.
  • The pharmacodynamic impact of MPA, specifically inosine monophosphate dehydrogenase (IMPDH) activity, remains understudied in pediatric NS.

Purpose of the Study:

  • To evaluate the pharmacodynamics of MPA by measuring IMPDH activity in children with NS.
  • To assess the relationship between MPA concentrations and IMPDH inhibition in this population.
  • To explore factors influencing MPA pharmacokinetics and pharmacodynamics, including age and lipid levels.

Main Methods:

  • A cohort of 21 children (4-16 years) with NS treated with mycophenolate mofetil was studied.
  • Plasma concentrations of MPA and its glucuronide were quantified using high-performance liquid chromatography-ultraviolet (HPLC-UV).
  • IMPDH activity was determined using a separate HPLC-UV method; variability was assessed by coefficient of variation (CV).

Main Results:

  • IMPDH activity and MPA trough concentrations (Ctrough) were measured, with significant variability observed.
  • A median of 61% maximum IMPDH inhibition was achieved.
  • MPA Ctrough and predicted AUC were lower than in previous studies; MPA clearance was higher in younger children.
  • IMPDH activity and inhibition levels were comparable to those in renal transplant recipients.

Conclusions:

  • IMPDH activity in children with NS is similar to that in renal transplant recipients and is not regulated by age or gender.
  • Variability in pharmacodynamic parameters was greater than in pharmacokinetic parameters.
  • MPA underexposure may occur more frequently in younger children, particularly those with high cholesterol and triglycerides, due to higher MPA clearance.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
148
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
288
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
259